about   CII home   shop   checkout
  • CONFERENCES
    • Upcoming Conferences
    • Key Conferences
    • CDs
    • Press Passes
    • Past Conferences
    • Meet Our Executive Producers
  • COURSES/SEMINARS
    • Short Courses
    • Virtual Workshops
    • Webinars
  • SPONSORSHIP/EXHIBIT
    • Sponsorship Opportunities
    • Event Prospectus
  • CHI SERVICES
    • Lead Generation
    • Co-Promoted Events
  • CHI DIVISIONS
    • Healthtech Publishing
    • Barnett International
    • ClinEco
    • Evaluating Biopharma
    • Insight Pharma Reports
Improve Translation of Humanized Animal Models for Immunotherapy
Biocytogen Boston Corp Logo
July 16, 2020
11 am to 12 pm EDT
 

Preview:

 

Webinar Description:

Despite significant advances have been made in developing novel therapeutics for cancer treatment, only about five percent of new cancer drugs are approved, and most fail due to lack of translation from preclinical results to clinical efficacy. The current preclinical methods including animal models are limited in predicting successful clinical outcomes. The development and application of humanized animal models, which mimic human immunity and therapeutic targets, may provide promising solution to the challenges of preclinical translation. The outline of this webinar includes:

  • Overview of current animal models in immunotherapy
  • The translatability limitations of current animal models
  • Improve the translation with humanized animal models

Learning Objectives:

  • Understand the limitation of current animal models in immunotherapy
  • Understand why a humanized model is needed
  • Understand the application of humanized animal models

Speaker:

Zhaoxue (Luke) Yu, PhD
Global Head of Preclinical Pharmacology
Biocytogen Boston Corp

Dr. Yu has more than 15 years of research and technical leadership experience in drug discovery and model design for immune/autoimmune rare genetic diseases, neurological diseases, tumors and metabolic diseases across various therapeutic modalities including antibodies, biologics, small molecules, mRNAs, and AAVs. Prior to Biocytogen, Dr. Yu served as a pharmacology technical leader at Gemini Pharmaceuticals, Achillion Pharmaceuticals, and Alexion Pharmaceuticals. Dr. Yu has been a major contributor to multiple drug development programs from preclinical to clinical stages, some of which have subsequently obtained success approvals by the FDA.

Dr. Yu received his Ph.D. in Neurobiology and M.D. in China. He has held postdoctoral research positions at institutions including Emory University, Yale University, and Boston Children’s Hospital. Dr. Yu is an established author of multiple publications in peer-reviewed journals and patents, in addition to being a speaker at several international conferences and seminars.

Click here to access
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Genomics

Healthcare

IT & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy